Search Results - "Bush, Jim"

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2 by Painter, Wendy P, Holman, Wayne, Bush, Jim A, Almazedi, Firas, Malik, Hamzah, Eraut, Nicola C J E, Morin, Merribeth J, Szewczyk, Laura J, Painter, George R

“…Molnupiravir, EIDD-2801/MK-4482, the prodrug of the active antiviral ribonucleoside analog ß-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a…”
Get full text

Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2 by Holman, Wendy, Holman, Wayne, McIntosh, Stacy, Painter, Wendy, Painter, George, Bush, Jim, Cohen, Oren

“…A recently published article described the safety, tolerability, and pharmacokinetic profile of molnupiravir (Painter et al. 2021), a novel antiviral agent…”
Get full text

A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects by Bush, Jim, Kawakami, Kazuki, Muniz, Rafael

“…FKB327 is a biosimilar of the adalimumab reference product (RP). The primary objective was to assess the relative bioavailability of FKB327 after a single…”
Get full text

Discovery and development of avotermin (recombinant human transforming growth factor beta 3): A new class of prophylactic therapeutic for the improvement of scarring by Occleston, Nick L., O'Kane, Sharon, Laverty, Hugh G., Cooper, Mark, Fairlamb, David, Mason, Tracey, Bush, Jim A., Ferguson, Mark W.J.

“…ABSTRACT Scarring in the skin following surgery or trauma may be associated with adverse aesthetic, functional, growth and psychological effects, such that…”
Get full text

Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria by Gaya, Anna, Munir, Talha, Urbano‐Ispizua, Alvaro, Griffin, Morag, Taubel, Jorg, Bush, Jim, Bhan, Ishir, Borodovsky, Anna, Wang, Yue, Badri, Prajakta, Garg, Pushkal

“…Complement dysregulation underpins the physiopathology of paroxysmal nocturnal hemoglobinuria (PNH). Cemdisiran, an RNA interference investigational treatment,…”
Get full text

Reduction of tendon adhesions following administration of Adaprev, a hypertonic solution of mannose-6-phosphate: mechanism of action studies by Wong, Jason K F, Metcalfe, Anthony D, Wong, Richard, Bush, Jim, Platt, Chris, Garcon, Arnaud, Goldspink, Nick, McGrouther, Duncan A, Ferguson, Mark W J

“…Repaired tendons may be complicated by progressive fibrosis, causing adhesion formation or tendon softening leading to tendon rupture and subsequent reduced…”
Get full text

Therapies with Emerging Evidence of Efficacy: Avotermin for the Improvement of Scarring by Bush, Jim, So, Karen, Mason, Tracey, Occleston, Nick L., O′Kane, Sharon, Ferguson, Mark W. J.

“…Many patients are dissatisfied with scars on both visible and non-visible body sites and would value any opportunity to improve or minimise scarring following…”
Get full text

Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting by Walele, Tanvir, Bush, Jim, Koch, Annelize, Savioz, Rebecca, Martin, Claire, O'Connell, Grant

“…The safety profile of Puritane™, a closed system electronic vapour product (EVP), was evaluated when used by smokers of conventional cigarettes (CCs) for 24…”
Get full text

A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks by Cravo, Ana S., Bush, Jim, Sharma, Girish, Savioz, Rebecca, Martin, Claire, Craige, Simon, Walele, Tanvir

“…A randomised, parallel group clinical study was performed to evaluate the safety profile of an e-vapour product (EVP; 2.0% nicotine) in smokers of conventional…”
Get full text

Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug–Drug Interaction Potential by Schultze-Mosgau, Marcus-Hillert, Höchel, Joachim, Prien, Olaf, Zimmermann, Torsten, Brooks, Ashley, Bush, Jim, Rottmann, Antje

“…Background and objectives In-vitro data suggest that clearance of vilaprisan is mediated by cytochrome P450 3A4 (oxidation) and aldoketoreductases (reduction)…”
Get full text

Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects by Harada, Tomohiko, Wilbraham, Darren, La Borderie, Guillemette, Inoue, Shinsuke, Bush, Jim, Camm, A. John

“…Aim Amiselimod (MT‐1303) is a selective sphingosine 1‐phosphate 1 (S1P1) receptor modulator which is currently being developed for the treatment of various…”
Get full text

A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects by Cheung, Dorothy, Fong, Alice, Ding, Han Ting, Cabanski, Christopher R., Wang, Jianshuang, Chen, Yuan, Bush, Jim, Harris, Jeffrey M., Pan, Lin

“…Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease. Although anti-fibrotic treatments, such as pirfenidone, are available that reduce…”
Get full text

Safety and efficacy of an extended‐release peptide YY analogue for obesity: A randomized, placebo‐controlled, phase 1 trial by Tan, Tricia M.‐M., Minnion, James, Khoo, Bernard, Ball, Laura‐Jayne, Malviya, Reshma, Day, Emily, Fiorentino, Francesca, Brindley, Charlie, Bush, Jim, Bloom, Stephen R.

“…Aim To report the results from a Phase 1 trial of an extended‐release peptide YY analogue, Y14, developed for the treatment of obesity. Methods Y14 was…”
Get full text

Mitigation of Initial Cardiodynamic Effects of the S1P 1 Receptor Modulator Ponesimod Using a Novel Up-Titration Regimen by Juif, Pierre-Eric, Hoch, Matthias, Vaclavkova, Andrea, Krause, Andreas, Bush, Jim, Dingemanse, Jasper

“…Ponesimod, a potent selective sphingosine-1-phosphate receptor 1 modulator, leads to a reduction in circulating total lymphocyte count and transient decreases…”
Get full text

Mitigation of Initial Cardiodynamic Effects of the S1P1 Receptor Modulator Ponesimod Using a Novel Up‐Titration Regimen by Juif, Pierre‐Eric, Hoch, Matthias, Vaclavkova, Andrea, Krause, Andreas, Bush, Jim, Dingemanse, Jasper

“…Ponesimod, a potent selective sphingosine‐1‐phosphate receptor 1 modulator, leads to a reduction in circulating total lymphocyte count and transient decreases…”
Get full text

SP200A SUBCUTANEOUSLY ADMINISTERED INVESTIGATIONAL RNAI THERAPEUTIC (ALN-CC5) TARGETING COMPLEMENT C5 FOR TREATMENT OF PNH AND COMPLEMENT-MEDIATED DISEASES:INTERIM PHASE 1 STUDY RESULTS by Najafian, Nader, Hill, Anita, Taubel, Jorg, Bush, Jim, Borodovsky, Anna, Kawahata, Noriyuki, Mclean, Helen, Partisano, Angela, Chaturvedi, Prasoon, Sorensen, Benny

Get full text

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results by Hill, Anita, Taubel, Jorg, Bush, Jim, Borodovsky, Anna, Kawahata, Noriyuki, Mclean, Helen, Powell, Christine, Chaturvedi, Prasoon, Warner, Garvin, Garg, Pushkal, Sorensen, Benny

“…Introduction: Uncontrolled complement activation plays a pivotal role in a variety of disorders such as PNH and aHUS. ALN-CC5 is a subcutaneous (SC)…”
Get full text

Effects of interleukin-10 on cutaneous wounds and scars in humans of African continental ancestral origin by Kieran, Ingrid, Taylor, Catherine, Bush, Jim, Rance, Mark, So, Karen, Boanas, Adam, Metcalfe, Anthony, Hobson, Rosalind, Goldspink, Nick, Hutchison, John, Ferguson, Mark

“…Scars in humans of African continental ancestry heal with an exaggerated inflammatory response and a generally wider scar. Interleukin‐10 is an…”
Get full text

Weight Loss With a Novel Peptide YY Analogue for Obesity: A Randomised, Placebo-Controlled Phase I Trial by Tan, Tricia, Minnion, James, Eu Khoo, Bernard Chong, Ball, Laura-Jayne, Malviya, Reshma, Day, Emily, Fiorentino, Francesca, Brindley, Charlie, Bush, Jim, Bloom, Stephen R

“…Abstract Background: Obesity and its co-morbidities remain a prime driver of global morbidity and mortality. Current therapies for obesity are limited in…”
Get full text

Surgical instruments, sutures and suturing techniques by Bush, Jim, Bayat, Ardeshir

“…Anthropological studies suggest that prehistoric man used various techniques to close skin wounds (Ellis, 2001). The jaws of termites or beetles were used to…”
Get full text